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Abstract 
The current mainstay of treatment in patients with thrombotic antiphospholipid syndrome (APS) is long-
term anticoagulation, mainly with Vitamin K antagonist agents.  Some recently available studies have 
created new ground for discussion about the possible discontinuation of anticoagulation therapy in 
patients with a history of thrombotic APS in whom antiphospholipid antibodies (aPL) are not detected any 
longer (i.e. aPL seroconversion).  
We report the main points discussed at the last CORA Meeting regarding the issue whether or not 
anticoagulation can be stopped after aPL seroconversion. In particular, we systematically reviewed the 
available evidence investigating the clinical outcome of APS patients with aPL seroconversion in whom 
anticoagulation was stopped when compared to those in whom therapy was continued regardless the aPL 
profile. Furthermore, the molecular basis for the aPL pathogenicity, the available evidence of non-criteria 
aPL and their association with thrombosis are addressed. 
To date, available evidence is still limited to support the indication to stop oral anticoagulation therapy in 
patients with a previous diagnosis of thrombotic APS who subsequently developed a negative aPL profile.  
The identification of the whole risk profile for cardiovascular manifestations and possibly of a second level 
aPL testing in selected patients with aPL might support the eventual clinical decision but further 
investigation is warranted. 
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1. Introduction 
High morbidity and mortality due to recurrence of thrombotic events is the main concern in patients with 
antiphospholipid syndrome (APS) [1]. Current evidence-based guidelines recommend long-term oral 
anticoagulation (OAC) as prophylaxis of new thrombotic manifestations of APS. The decision on the 
duration and intensity of this treatment should be based on the clinical features and immunological profile. 
According to the guidelines, patients with definite APS and a first venous thrombotic event should receive 
long-term OAC to an international normalized ratio (INR) target of 2.0–3.0 (the so called conventional-
intensity anticoagulation). On the other side, patients with definite APS and an arterial thrombotic event 
should receive high-intensity anticoagulation therapy to an INR target between 3.0 and 4.0. However, long-
term OAC has also been associated to a wide broad of hemorrhagic complications [2]. 
Especial attention has recently been payed to a small subset of patients who fulfill APS criteria but in whom 
aPL become persistently negative [3].  
We systematically reviewed the available evidence investigating the clinical outcome of APS patients with 
aPL seroconversion (negativization) in whom anticoagulation was stopped when compared to those in 
whom therapy was continued regardless the aPL profile. Moreover, we aim to discuss the molecular basis 
for the aPL pathogenicity and the available evidence of non-criteria aPL and their association with 
thrombosis.   
2. Systematic Review of the available evidence on aPL seroconversion. 
The aim of this systematic review is to identify the available evidence on the clinical experience of 
thrombotic APS patients with persistent negative aPL. We also focused on those cases where 
anticoagulation was stopped after patients showed persistent negativity to conventional aPL tests. 
2.1 Methods. 
We performed a systematic review to identify and include in our study articles that reported clinical 
experience of thrombotic APS patients with persistent aPL seroconversion and patients that were 
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discontinued anticoagulation for that reason. Key words and subject terms used in the search included: 
("antiphospholipid antibodies"[MeSH Terms] OR "aPL"[All Fields]) AND ("negativization"[All Fields]) AND 
("anticoagulation"[All Fields] OR "treatment"[All Fields] AND "phospholipid"[All Fields]) OR 
("antiphospholipid syndrome"[MeSH Terms+ OR ("APS” *All Fields+). 
The search strategy was applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citation, EMBASE, 
Cochrane Central Register of Controlled Trials and Scopus from 1983 (year when the antiphospholipid 
syndrome was firstly described) to present; abstracts from EULAR and ACR were also screened. Inclusion 
criteria included either: a) follow up of thrombotic APS patients with persistent aPL seroconversion b) 
follow-up of thrombotic APS patients with persistent aPL seroconversion that were discontinued 
anticoagulation therapy. Studies that met the above-mentioned criteria were systematically analyzed by 
two independent reviewers (MR and IC). Disagreements were resolved by consensus; if consensus could 
not be achieved, a third party (SS) provided an assessment of eligibility. As the data on eligibility were 
dichotomous (eligible: yes/no), inter-rater agreement at both the title and abstract review and the full 
article review stages was determined by calculation of Cohen’s kappa coefficient (k=0.85). 
2.2 Results. 
Out of 1006 screened studies, a total of four [3–6] met the inclusion criteria, including 47 thrombotic APS  
patients with persistently aPL seroconversion. Three out of four studies, including 23 thrombotic APS 
patients, described discontinuation of anticoagulation therapy after aPL seroconversion.  
Characteristics of retrieved studies are summarized in Table 1. 
2.2.1 Definition of aPL negativization. 
The definition of aPL seroconversion/negativization was heterogeneous among studies. Two studies [4,5] 
included patients with 2 consecutive aPL seroconversion, however one of those studies [5] retested 
patients to confirm aPL disappearance after five years. Two studies [6,7] did not define the aPL 
negativization, however one study [7], reported patients with at least nine negative determinations of 
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criteria aPL testing. Of note, one study reported patients positive for aCL IgG at low titer in most cases and 
one patients positive for LA only but with negative results in a second determination [4]. Another study 
included mainly patients positive for LA only [5]; only one study [6] tested their cohort of patients for non-
criteria aPL (anti-annexin A5 antibodies). Anti-beta 2 glycoprotein I (2GPI) antibodies were not 
investigated in all the reported studies. 
2.2.2 Follow up and Recurrences. 
Medina and colleagues [5], investigated 24 primary APS patients with aPL seroconversion in a retrospective 
study, without stopping anticoagulation therapy. Since aPL disappearance and after 60 months of follow 
up, 11 out of 24 patients (45.8%) presented recurrence of thrombosis despite the continuation of the 
anticoagulant treatment. Among these 11 patients, 9 presented a DVT, one experienced an ischemic stroke 
and one patient developed pulmonary artery hypertension. 9 out of 24 patients (37.5%) had a past history 
of arterial thrombotic events (eight strokes and one mesenteric thrombosis) before aPL disappearance. This 
fact could place this group of patients at a higher thrombotic risk category. In addition, other non-
thrombotic or non-criteria APS manifestations occurred in 6 patients, such as chronic skin ulcers in lower 
extremities in 4 patients and severe thrombocytopenia in two. Comarmond and colleagues [6] included 10 
APS patients with prolonged disappearance of antiphospholipid antibodies (aPL) in whom anticoagulation 
therapy was discontinued. After a median duration of follow-up of 19 months (4-66.75) since the cessation 
of oral anticoagulantion, one out of 10 patients relapsed developing pulmonary embolism. The remaining 
two studies [4,7], included 6 primary APS and 7 primary APS patients, respectively.  Anticoagulation therapy 
was discontinued in both studies and after a follow-up of 21 ± 12 months and 18 months, respectively, no 
recurrences were found.  
The results of this systematic review seem to suggest that it is possible to discontinue antithrombotic 
treatment in some patients with primary APS in whom aPL became persistently negative. However, 
altogether these reports do not allow to get a clear conclusion about the withdrawal of VKA treatment 
based on the analysis of the literature.  
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3. Molecular basis for the antiphospholipid antibody pathogenicity. 
The underlying mechanisms by which aPL can induce a thrombophilic phenotype and clinical 
manifestations are still under investigation. In this section, we will review the available evidence on 
molecular basis for aPL pathogenicity based mainly on the studies carried out by a group of the authors of 
the present manuscript (SS, RM, BML, LPC, CMJ). The aim to review these mechanisms is to show the 
profound changes that aPL induces at different levels of coagulation and inflammatory pathways. 
3.1 Tissue factor and endothelial dysfunction.  
Pro-coagulant cell activation, accompanied with tissue factor (TF) expression, and TF pathway up regulation 
are key events explaining the pathophysiology of thrombosis in patients with APS [8]. In addition, it has 
been shown that TF signalling activities in APS, induced by aPL, are mainly mediated by protease-activated 
receptors (PARs). Accordingly, PAR1- and PAR2-induced signalling is directly involved in the constitutive 
mitogen-activated protein kinase (MAPK) activation [9] and the increased expression of the pro-
inflammatory cytokine vascular endothelial growth factor (VEGF) and its receptor Flt1 [10]. Similar results 
have been reported in endothelial cells (ECs),platelets, and monocytic cell lines and in in vivo models of 
aPL-induced thrombogenicity [11–13]. 
aPL are also responsible for the altered protein profile of monocytes related to thrombosis development, 
including deregulated expression of annexin A1 (AnxA1), annexin A2 (AnxA2), ubiquitin Nedd8, Rho A 
protein, PDI and Hsp60. These proteins have been shown to be associated with the induction of a pro-
coagulant state, as well as autoimmune-related responses [14]. 
Early endothelial dysfunction [15] and increased carotid intima media thickness (CIMT) have been also 
observed in APS [16]. In a recent study, including a cohort of 43 APS patients, higher aPL-IgG titers showed 
a strong association with the development of thrombotic events and carotid intima-media thickness 
increase [17].  
3.2 Oxidative Stress. 
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Several studies have evidenced that oxidative stress is directly involved in the pathophysiology of some APS 
features. In the setting of APS, aCL antibodies seem to play an important role in the oxidative status by 
inducing nitric oxide (NO) and superoxide production, resulting in enhanced levels of plasma peroxynitrite, 
a powerful pro-oxidant substance [18]. aCL antibodies levels positively correlated with plasma levels of F2-
isoprostanes, sensitive markers of in vivo lipid peroxidation, indicating enhanced oxidative stress in APS 
[19,20].  
Perez-Sanchez et al showed [17] an increased production of reactive oxygen species (ROS) by monocytes 
and neutrophils in APS that disturbs the redox status and in turn may influence the expression of 
prothrombotic and proinflammatory molecules.   
3.3 Toll like receptors. 
Different studies have demonstrated that up-regulation of Toll-like receptors (TLR) is playing a role in APS 
pathogenesis. Both TLR4 on endothelial cells and TLR 7 & 8 in plasmacytoid dendritic cells and monocytes 
respectively, can be modulated by aPL eventually inducing biological responses in the cells [21, 22]. 
3.4 NETosis. 
Apart from the generation of ROS and the release of microbicidal molecules from granules, antimicrobial 
activity called neutrophil extracellular traps (NETs) activation and release (or NETosis), has recently been 
described and can promote tissue damage, thrombosis, atherosclerosis and autoimmunity. NET generation 
has been recognized as an important activator of the coagulation cascade, being deeply associated with 
deep vein thrombosis [23]. NETs can regulate thrombosis through several mechanisms, accordingly NETosis 
has been suggested to represent an additional mechanism of thrombosis mediated by aPL.  Knight and co-
workers recently showed that NETs circulate at high levels in the plasma of APS patients, even between 
thrombotic episodes [24]. Indeed, freshly isolated neutrophils from APS patients are primed to undergo 
spontaneous NETosis when cultured ex vivo. Mechanistically, anti-β2GPI IgG promotes NETosis by engaging 
β2GPI protein on the neutrophil surface; this process is independent of the Fc receptor, but does require 
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ROS production and TLR4 signalling. Further, and pointing to disease relevance, anti-β2GPI-stimulated NETs 
promote thrombin generation in vitro and in vivo [25].  
3.5 Genomic and epigenetic. 
aPL are also able to induce genomic and epigenetic modulation, creating a pro-thrombotic state. A recent 
study by Perez-Sanchez et al. described specific gene profiles in monocytes from APS patients, explaining 
the pro-atherothrombotic alterations (mainly related to aPL titres, and promoted in vitro by aPL) [26].  
Current genome-wide studies have further shown that the human genome is pervasively transcribed and 
produces many thousands of regulatory non-protein-coding RNAs (ncRNAs), including microRNAs, small 
interfering RNAs, and various classes of long ncRNAs. It is now clear that these RNAs fulfil critical roles as 
transcriptional and post-transcriptional regulators and as guides of chromatin-modifying complexes. 
Among them, miRNAs are small ncRNAs ubiquitously expressed, have a profound influence in the immune 
system and a relevant role in the pathogenesis of autoimmune disorders. Preliminary studies have shown 
that several members of the miR 17‐92 cluster (miR‐20a and miR‐19b) regulate the expression of TF in 
monocytes from patients with APS and systemic lupus erythematosus (SLE) [27]. A reduction in their 
expression has been found to significantly correlate with the over‐activation of TF. The reduction in the 
expression of these miRNAs could therefore contribute to the prothrombotic state characteristic of APS 
and SLE patients [27]. 
The relevance of these mechanisms, when considering stop anticoagulation, relies on the following open 
question:  are these profound changes in thrombotic, inflammatory and oxidative status reversible when 
aPL become negative? Moreover, if this is the case, how long after negativitation of aPL all these changes 
are back regulated? 
4.  Non-classification criteria antiphospholipid antibodies and thrombosis. 
Data gathered in recent years explored the relationship between three groups of antiphospholipid 
antibodies, not currently included in the classification criteria and the development of thrombotic events. 
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In this section, we will summarize available data on Prothrombin/phosphatidylserine complex, antibodies 
directed to the Domain I of 2GPI and IgA aPL, and their association with thrombotic risk. 
4.1. Prothrombin/phosphatidylserine complex. 
Early reports suggest an association between APS and antibodies to prothrombin, directed either to 
prothrombin in solid phase (aPT) or to a complex of phosphatidylserine/prothrombin (aPS/PT). While these 
antibodies are known to be directed to the same molecule, they differ in their immunological 
characteristics and clinical associations [28]. Emerging evidence supports the clinical utility of aPS/PT over 
that of aPT in the setting of APS [29].   A recent systematic review of the topic analyzed available data on 
more than 7000 patients and controls from 38 studies on aPT and 10 studies on aPS/PT. aPS/PT was 
associated with both arterial and/or venous thrombosis and this association was stronger for aPS/PT when 
compared to aPT (OR 5.11 [95%CI 4.2-6.3] vs. 1.82 [95%CI 1.44-2.75], respectively) [30]. Data coming from 
a study in 265 Japanese patients with systemic autoimmune diseases showed that aPS/PT conferred a 3.6 
fold increase risk for APS [31]. Several studies that followed confirmed the association between aPS/PT and 
the clinical manifestations of APS [32,33]. A large study in a cohort of 728 patients suspected of having APS, 
in the absence of aCL or anti-β2GPI showed that 41 of them (5.6%) had elevated levels of aPS/PT with 
thrombotic events occurring in 50% of these cases [34]. This finding strongly suggests that aPS/PT may 
represent a valuable diagnostic test in a small group of patients with APS like manifestations even in the 
absence of classification laboratory criteria. 
When evaluating the diagnostic accuracy of several aPL specificities combinations, the profile including LA + 
anti-β2GPI + aPS/PT held the best diagnostic accuracy for APS even when subdividing the study group into 
those with thrombosis and those with pregnancy loss [29]. In addition, aPS/PT have been confirmed as a 
strong risk factors for thrombosis, irrespective of the site and type of thrombosis. Their presence incurred 
in an odds ratio (OR) for thrombosis 3 to 18 times higher than in various control groups [29]. 
While a close association has been reported between aPS/PT and the LA, our data showed that aPS/PT and 
LA are not interchangeable tests but independent, and therefore, additive risk factors for thrombosis [35]. 
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4.2 Antibodies directed to the Domain I of 2GPI. 
Anti-2GPI antibodies have been reported to target each of the 5 different domains of the 2GPI 
molecule [36]. However, it is the N-terminal domain, designated domain I (or DI), that has been described 
of importance in the pathogenesis of APS [37,38]. De Laat et al reported that positivity for anti-DI is 
associated with an increased risk of thrombosis [39]. A subsequent multicenter study by the same group 
[40] reported a 3.5-fold increase in the risk of developing vascular thrombosis in patients positive for IgG 
anti-DI when compared with those without this antibody. In addition, the risk of having pregnancy 
morbidity in this population also displayed a 2.4-fold increase. High-risk APS patients, those with triple 
positivity for aPL, including aCL, anti-2GPI and the LA, have been reported to also have higher titers of 
circulating anti-DI when compared with those with double or single aPL positivity [41]. A recent study from 
Pericleous et al has reported that not only positivity for IgG anti-DI but also for the IgM and IgA isotypes of 
anti-DI are strongly associated with APS [42]. In addition, using the novel β2GPI-DI chemiluminescence 
assay (CLIA), Mahler et al showed an OR for thrombosis of 9.5 in a cohort of 106 patients with APS and high 
levels of anti-DI [43]. 
Anti-DI antibodies are of increased clinical interest, indeed. However, it is now clear that not all anti-β2GPI 
target DI, and some anti-β2GPI react with other domains of the β2GPI molecule. Antibodies to DIV/V have 
been reported in asymptomatic patients, leprosy, and in children with atopic dermatitis [44,45]. In this 
respect, anti-DIV/V antibodies were reported among asymptomatic aPL carriers, those with no evidence of 
aPL-related clinical manifestations or any underlying autoimmune disease. In this study, the authors 
suggested that the ratio between antibodies to DI versus DIV/V might be predictive for systemic 
autoimmunity [46].  
While anti-D1 antibodies seem to be higher predictive for thrombotic manifestations than the test against 
the native molecule, anti-D1 assay displays a lower sensitivity suggesting that anti-D1 cannot substitute the 
standard test in the routine [47]. There are actually anecdotal reports of anti-D1 positivity with negativity 
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for anti-β2GPI molecule (and for other aPL), but the values were in the borderline area and further studies 
are necessary to investigate such an aspect [47]. 
4.3 IgA aPL 
Controversy still exist as to whether patients with features of APS, negative for other IgG or IgM aPL, may 
benefit from IgA aPL testing and, if they are tested and found positive, their clinical relevance [48]. In 
general, IgA aPL are found in association with other isotypes (i.e., IgG and/or IgM), and mainly associate to 
skin ulcers, Raynaud’s phenomenon, livedo, or cutaneous vasculitis [49]. In addition, these antibodies have 
been reported as the dominant isotype in Afro-Caribbeans [50] and in Afro-Americans [51], usually present 
transiently or at low or moderate titers and in the absence of any aPL related clinical manifestation.  
Interestingly, recent data from the transplantation field suggest that pretransplant IgA aPL, specifically IgA 
anti-β2GPI, may serve as an independent risk factor for early graft thrombosis after renal transplantation 
[52], attributing a potential new role for IgA aPL as a biomarker for early transplant failure. 
4.4 Anti-annexin A5 and antivimentin antibodies 
Other antibody specificities, including anti-annexin A5 and antivimentin antibodies, might be eligible for 
thrombotic risk assessment just in selected patients, particularly when other aPL tests are negative with the 
presence of clinical APS signs and/or symptoms. Indeed, further investigations are needed to assess their 
role in the diagnostic algorithm for APS [53].  
Of note, very recently, Conti et al. [54] described a patient with catastrophic APS, the most severe variant 
of the disease, who tested negative to the conventional aPL but positive for aPL in thin layer 
chromatography immunostaining and vimentin/cardiolipin antibodies by ELISA test, highlighting how 
relevant non-criteria antibodies, in selected cases, can potentially be. However, anti-vimentin antibodies 
have been found in a wide panel of systemic autoimmune diseases in addition to APS, raising the question 
of their specificity [55]. 
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To date, laboratory criteria for APS include the assays test for the presence of LA, aCL and anti-β2GPI 
antibodies, however, in patients with persistent disappearance of aPL, some authors suggest a second 
level screening of non-criteria aPL before stopping the anticoagulant treatment.  
 
5. Conclusions 
aPL seroconversion and its definition is a rising topic of interest in the field of APS. Although there are 
reports in the literature supporting the discontinuation of antithrombotic treatment in some patients with 
primary APS in whom aPL became persistently negative, we still do not have enough data to make sound 
recommendation whether or not and when stopping oral anticoagulation therapy in APS patients with 
seroconversion.  
In particular, there is concern about the changes induced by aPL in pro-thrombotic and pro-inflammatory 
status and whether or not such biological changes can disappear at the same time of the seroconversion. 
The disappearance of formal classification aPL tests should be confirmed over time and second-level 
diagnostic test should be also investigated. In addition, the whole cardiovascular risk profile should be also 
evaluated.  
Ideally, OAC thromboprophylaxis should be withdrawn when the risks of this therapy outweigh the risks of 
thrombotic recurrence. In this sense, the following definition of low-risk profile for thrombotic recurrence 
after OAC discontinuation could be: no more than a single prior non-critical first venous thrombotic event in 
the presence of a known transient precipitating risk factor (smoking, hypertension, recent surgery, etc.) 
together with a low-risk aPL profile (single aPL that becomes persistently negative over a long period of 
time; i.e., more than 2 years).  
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Table 1. The table reports the main characteristics of the four studies that met the inclusion criteria on aPL seroconversion. 
Study, year Criado-García et al. 2008 Medina et al. 2017 Comarmond et al. 2017 Bazàn et al. 2017 
Study's design  Prospective Retrospective Retrospective Retrospective 
 Patients 6 Primary APS 24 Primary APS 10 APS  7 Primary APS 
Previous LA positivity (%) 16,70% N/A N/A 86% 
Previous aCL  (IgG/IgM) 
positivity (%) 
100% 87,50% N/A 28,60% 
Previous anti-β2GPI (IgG/IgM)       
positivity (%) 
0% N/A N/A 0% 
Non Criteria aPL tested N/A anti-annexin A5 antibodies N/A N/A 
Time of aPL positivity 
(months) 
10-53 109,4 ± 80,7 N/A 
At least two aPL determinations, 
performed 12 weeks apart 
Mean time of anticoagulation 
therapy (months) 
25 ± 18 N/A 21 (9–118) 111 ± 52,4 
Definition of aPL 
negativization  
2 consecutive  negative  
determinations 
≥2 subsequent negative aPL determinations, 
retested after 5 years 
N/A 
At least nine negative 
determinations 
Follow up after 
anticoagulation 
discontinuation (months) 
21 ± 12 60 19 (4–66.75) 18 
Recurrences at follow-up  None  
45.8%: DVT in 37,5%, ischemic stroke in 
4,2%, pulmonary artery hypertension in 
4,2%. Other non-thrombotic APS 
manifestations were chronic ulcers in lower 
extremities and severe thrombocytopenia 
One out of 10 patients 
(10%) relapsed developing 
PE 
None  
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